CADL vs CCCC

Candel Therapeutics, Inc. vs C4 Therapeutics, Inc. — Valuation Comparison 2026

CADL

Biological Products, (No Diagnostic Substances)
Candel Therapeutics, Inc.
Quality
4.4
out of 10
Value Trap
38
LOW
Price
$8.30
Last close
Models
8/13
Active
VS

CCCC

Biological Products, (No Diagnostic Substances)
C4 Therapeutics, Inc.
Quality
5.3
out of 10
Value Trap
24
SAFE
Price
$4.37
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType CADL Fair ValueCADL Upside CCCC Fair ValueCCCC Upside
Bayesian DCF Intrinsic $3.24 -60.9% $0.70 -84.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.10 -98.5% $0.26 -91.2%
Dynamic NAV Asset-Based $2.44 -70.6% $1.86 -57.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CADL vs CCCC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CADL vs CCCC — Which Stock Is More Undervalued?

CCCC scores higher with a 5.3/10 quality rating vs CADL's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Candel Therapeutics, Inc. (CADL) and C4 Therapeutics, Inc. (CCCC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CADL currently trades at $8.30 with a QOC of 4.4/10, while CCCC trades at $4.37 with a QOC of 5.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).